Effectiveness Evaluation of Additional Risk Minimization Measures for Adolescent Use of Aripiprazole in the European Union: Results from a Post-Authorization Safety Study
Authors:
Open Access
- 18 April 2018
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 41 (8) , 797-806
Abstract
Two risk minimization (RM) tools—a healthcare professional frequently asked questions (HCP-FAQs) brochure and a patient/caregiver information brochure (PCIB)—were developed for HCPs and for adolescents (aged ≥ 13 years) receiving aripiprazole for bipolar I mania and their caregivers.Keywords
Funding Information
- Otsuka Pharmaceutical Europe Ltd
This publication has 16 references indexed in Scilit:
- Unmet needs in paediatric psychopharmacology: Present scenario and future perspectivesEuropean Neuropsychopharmacology, 2015
- Bipolar Disorder in ChildrenPsychiatry Journal, 2014
- Post-Approval Evaluation of Effectiveness of Risk Minimisation: Methods, Challenges and InterpretationDrug Safety, 2013
- A Descriptive Study of Additional Risk Minimization Measures Included in Risk Management Plans Reviewed by the United Kingdom Regulatory AuthorityPharmaceutical Medicine, 2013
- Systematic review of the prevalence of bipolar disorder and bipolar spectrum disorders in population-based studiesTrends in Psychiatry and Psychotherapy, 2013
- Impact of Regulatory Guidances and Drug Regulation on Risk Minimization Interventions in Drug SafetyDrug Safety, 2012
- Risk Minimization Activities of Centrally Authorized Products in the EUDrug Safety, 2012
- Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and AdolescentsJournal of Child and Adolescent Psychopharmacology, 2011
- Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight GainJAMA, 2008
- A Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Aripiprazole in Patients With Acute Bipolar ManiaAmerican Journal of Psychiatry, 2003